A soluble divalent class I MHC/IgG₁ fusion protein activates CD8+ T cells in vivo

详细信息    查看全文

• 作者：Carey ; Brenna ; DeLay ; Monica ; Strasser ; Jane E. ; Chalk ; Claudia ; Dudley-McClain ; Kristen ; Milligan ; Gregg N. ; et. al.
• 关键词：MHC ; T lymphocytes ; CTL ; Tumor immunity ; Viral immunity ; Vaccination
• 刊名：Clinical Immunology
• 出版年：2005
• 出版时间：July, 2005
• 年：2005
• 卷：116
• 期：1
• 页码：65-76
• 全文大小：442 K

文摘

CD8+ T lymphocytes recognize tumor and viral antigens bound to class I major histocompatibility complexes (MHC). Tumors and viruses may evade detection by preventing antigen presentation. The present study was designed to determine whether a soluble divalent fusion protein, containing the extracellular domains of a class I MHC molecule fused to β2-microglobulin and the constant domains of IgG1, could induce an immune response in vivo. Administration to mice of the fusion protein loaded with a tumor peptide induced peptide-specific T cell activation and retarded tumor growth. Administration of the fusion protein loaded with a glycoprotein B (gB) peptide derived from herpes simplex virus type 1 (HSV-1) induced gB-specific cytotoxic T lymphocytes and protected mice from a lethal HSV-1 challenge. These data suggest that antigen-loaded MHC/IgG fusion proteins may enhance T cell immunity in conditions where antigen presentation is altered.